What changed, and when

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

locations: 743 sites · Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Slovakia, Spain, Turkey (Türkiye), Ukraine, United Kingdom, United States → 742 sites · Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Slovakia, Spain, Turkey (Türkiye), Ukraine, United Kingdom, United States

CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.

Canadian journal of physiology and pharmacology · Other

Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.

Clinical oral investigations · Review

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

Nature metabolism · Mechanistic / preclinical research

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.

Rapid communications in mass spectrometry : RCM · Other

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

Eli Lilly and Company · Safety update

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

locations: 565 sites · Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States → 563 sites · Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Eli Lilly and Company · Phase 3 result

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Eli Lilly and Company · Regulatory update

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

Eli Lilly and Company · Phase 3 result

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

Cell metabolism · Mechanistic / preclinical research

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.

Lancet (London, England) · Clinical trial results

Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?

Expert opinion on investigational drugs · Other

Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943.

STAR protocols · Other

Retatrutide: a triple incretin receptor agonist for obesity management.

Expert opinion on investigational drugs · Other

Retatrutide showing promise in obesity (and type 2 diabetes).

Expert opinion on investigational drugs · Review

Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.

JAMA · Other

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

Lancet (London, England) · Clinical trial results

The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.

Diabetes, obesity & metabolism · Other

[From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism.].

Orvosi hetilap · Review

Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

The New England journal of medicine · Editorial / commentary

Enteroendocrine cell regulation of the gut-brain axis.

Frontiers in neuroscience · Review

Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.

Current diabetes reviews · Review

At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.

JAMA · Other

Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.

Alimentary pharmacology & therapeutics · Review

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Expert opinion on pharmacotherapy · Review

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.

Endocrinology and metabolism (Seoul, Korea) · Review

Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.

Health science reports · Primary clinical research

Recent advances in peptide-based therapies for obesity and type 2 diabetes.

Peptides · Primary clinical research

Rare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies.

European journal of pediatrics · Review

Top studies of 2023 relevant to primary care: From the PEER team.

Canadian family physician Medecin de famille canadien · Review

Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.

Gastroenterology report · Review

A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.

European journal of clinical pharmacology · Review

Advancements in the management of obesity: a review of current evidence and emerging therapies.

Expert review of endocrinology & metabolism · Review

Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

Expert opinion on pharmacotherapy · Review

Gut hormones and appetite regulation.

Current opinion in endocrinology, diabetes, and obesity · Review

Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review.

The lancet. Diabetes & endocrinology · Meta-analysis

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Nature medicine · Clinical trial results

Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.

American journal of therapeutics · Meta-analysis

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.

Cell discovery · Editorial / commentary

Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.

CNS drugs · Review

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.

Indian journal of endocrinology and metabolism · Review

Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care.

Biomedicines · Review

The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · Review

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?

Diabetes care · Review

Retatrutide.

Clinical diabetes : a publication of the American Diabetes Association · Other

Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.

Pharmaceuticals (Basel, Switzerland) · Review

The First Triple Agonist for Antiobesity: Retatrutide.

Cardiology in review · Primary clinical research

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.

Diabetes care · Review

Incretin-based therapies for the treatment of obesity-related diseases.

npj metabolic health and disease · Review

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.

Metabolism: clinical and experimental · Meta-analysis

Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.

Metabolism open · Review

The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · Primary clinical research

Why are we still in need for novel anti-obesity medications?

The Lancet regional health. Europe · Review

The power of three: Retatrutide's role in modern obesity and diabetes therapy.

European journal of pharmacology · Review

Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.

Endocrine · Mechanistic / preclinical research

Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.

Annual review of pharmacology and toxicology · Review

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.

Journal of pharmaceutical policy and practice · Other

Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.

Expert review of clinical pharmacology · Meta-analysis

Emerging pharmacotherapies for obesity: A systematic review.

Pharmacological reviews · Meta-analysis

Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.

npj metabolic health and disease · Mechanistic / preclinical research

Triple Agonism Based Therapies for Obesity.

Current cardiovascular risk reports · Review

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.

Annals of internal medicine · Meta-analysis

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.

Frontiers in endocrinology · Meta-analysis

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.

Proceedings (Baylor University. Medical Center) · Review

What is the pipeline for future medications for obesity?

International journal of obesity (2005) · Review

Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Mechanistic / preclinical research

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.

Obesity pillars · Primary clinical research

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.

Expert opinion on investigational drugs · Review

Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.

Journal of diabetes · Meta-analysis

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.

Cureus · Review

Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.

Polish archives of internal medicine · Review

Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Journal of diabetes · Meta-analysis

[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?].

Der Nervenarzt · Review

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Peptides · Review

Retatrutide-A Game Changer in Obesity Pharmacotherapy.

Biomolecules · Review

Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.

Diabetes technology & therapeutics · Meta-analysis

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.

Kidney international reports · Primary clinical research

Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.

Pharmacological reviews · Review

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

Journal of basic and clinical physiology and pharmacology · Meta-analysis

Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.

Drugs in context · Review

Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies.

Medicines (Basel, Switzerland) · Review

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.

The lancet. Diabetes & endocrinology · Clinical trial results

Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.

World journal of cardiology · Review

Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.

Acta diabetologica · Meta-analysis

Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies.

Panminerva medica · Review

Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Endocrinology, diabetes & metabolism · Meta-analysis

Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs.

World journal of diabetes · Review

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

The Journal of clinical endocrinology and metabolism · Meta-analysis

The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.

Cureus · Review

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.

Diabetes, obesity & metabolism · Clinical trial results

Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.

Diabetes, obesity & metabolism · Editorial / commentary

Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.

World journal of gastroenterology · Review

Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.

Journal of medicinal chemistry · Other

Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · Review

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

Obesity (Silver Spring, Md.) · Meta-analysis

Weight management treatment in obesity.

Medicina clinica · Review

Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.

Medicina (Kaunas, Lithuania) · Meta-analysis

Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.

Cureus · Review

Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.

Journal of clinical medicine · Review

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.

Journal of obesity · Review

Contractile effects of retatrutide in isolated mouse atrial preparations.

Naunyn-Schmiedeberg's archives of pharmacology · Mechanistic / preclinical research

Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.

Diabetes, obesity & metabolism · Clinical trial results

Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.

Diabetes, obesity & metabolism · Review

Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.

American journal of physiology. Gastrointestinal and liver physiology · Mechanistic / preclinical research

Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.

Obesity pillars · Primary clinical research

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

comparator: — → Placebo

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

intervention: — → Drug: Retatrutide; Drug: Placebo

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

secondary_endpoints: — → Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events (MACE-3); Time to First Occurrence of Composite Endpoint of CV death, or hospitalization or urgent visit due to HF; Time to Occurrence of All-Cause Death; Time to First Occurrence of composite endpoint of ≥ 40% Sustained Decline in eGFR, End-Stage Renal Disease (ESRD), or Renal Death; Percentage change from Baseline in Albuminuria urinary albumin/creatinine ratio (UACR) in Participants with UACR ≥30 mg/g (0.03 mg/mg) at baseline

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

primary_endpoints: — → Time to First Occurrence of Composite Endpoints; Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

study_completion: — → 2029-02-01

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

status: Recruiting → Active, not recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

primary_completion: 2029-12-31 → 2029-02-01

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

locations: — → 743 sites · Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Slovakia, Spain, Turkey (Türkiye), Ukraine, United Kingdom, United States

TRIUMPH-1

enrollment: 2140 → 2335

TRIUMPH-1

locations: — → 134 sites · Australia, Brazil, Canada, Hungary, India, Mexico, Poland, Puerto Rico, Romania, Spain, United Kingdom, United States

TRIUMPH-1

comparator: — → Placebo

TRIUMPH-1

intervention: — → Drug: Retatrutide; Drug: Placebo

TRIUMPH-1

secondary_endpoints: — → Percent Change from Baseline in Body Weight in Participants with Baseline BMI ≥ 35 kg/m2; Percentage of Participants who Achieve Body Weight Reduction of ≥ 5%; Percentage of Participants who Achieve Body Weight Reduction of ≥ 10%; Percentage of Participants who Achieve Body Weight Reduction of ≥ 15%; Percentage of Participants who Achieve Body Weight Reduction of ≥ 20%; Percentage of Participants who Achieve Body Weight Reduction of ≥ 25%; Percentage of Participants who Achieve Body Weight Reduction of ≥ 30%; Percentage of Participants who Achieve Body Weight Reduction of ≥ 35%; Change from Baseline in Waist Circumference; Change from Baseline in Systolic Blood Pressure (SBP); Percent Change from Baseline in Triglycerides; Percent Change from Baseline in Non-High-Density Lipoprotein (HDL)-Cholesterol; Percent Change form Baseline in Fasting Insulin; Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP); Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score; Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite-CT) Physical Function Composite Score; Change from Baseline in IWQOL-Lite-CT Psychosocial Composite Score; Change from Baseline in Body Mass Index (BMI); Percentage of Participants who Achieve Waist-to-Height Ratio (WHtR) <0.5; Change from Baseline in HbA1c; Change from Baseline in Estimated Glomerular Filtration Rate (eGFR); Percentage of Participants with a Change in Medication Use; Percentage of Participants who Develop Type 2 Diabetes; Time to Onset of Type 2 Diabetes; Percent Change from Baseline in AHI for GSA1 Subset; Percentage of Participants with ≥50% AHI Reduction from Baseline for GSA1 Subset; Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA1 Subset; Percent Change from Baseline in Sleep Apnea-Specific Hypoxic Burden for GSA1 Subset; Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form Sleep-related Impairment 8a T-score for GSA1 Subset; Change from Baseline in AHI Events Per Hour for GSA1 Subset in Participants with Baseline Body Mass Index (BMI) ≥ 35 kg/m2; Percentage of Participants who Achieve AHI < 5 for GSA1 Subset; Change from Baseline in ESS Score for GSA1 Subset; Change from Baseline in Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score; Change from Baseline in PROMIS Sleep Disturbance Short Form 8b T-Score for GSA1 Subset; Change from Baseline in Neck Circumference for GSA1 Subset; Change from Baseline in the WOMAC Physical Function Subscale Score for GOA1 Subset; Percentage of Participants who Achieve ≥ 50% Reduction in the WOMAC Pain Subscale for GOA1 Subset; Percentage of Participants who Achieve ≥ 50% Reduction in the WOMAC Physical Function Subscale for GOA1 Subset; Change from Baseline in the WOMAC Pain Subscale Score for GOA1 Subset with Baseline BMI ≥ 35 kg/m2; Change from Baseline in the WOMAC Stiffness Subscale Score for GOA1 Subset; Change from Baseline in the WOMAC Total Score for GOA1 Subset; Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score for GOA1 Subset; Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score for GOA1 Subset; Percentage of Participants with an Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function for GOA1 Subset; Percentage of Participants with an Improved Categorical Shift in PGIS - Target Knee Pain for GOA1 Subset; Change from Baseline in EQ-5D-5L for GOA1 Subset; Percentage of Participants with a Change in Use of Allowed Concomitant Pain Medication for GOA1 Subset; Change from Baseline in Joint Space Width for GOA1 Subset; Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)

TRIUMPH-1

primary_endpoints: — → Percent Change From Baseline in Body Weight; Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset; Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset; Percent Change from Baseline in Body Weight in Participants in Extension Subset

TRIUMPH-1

study_completion: — → 2026-04-30

TRIUMPH-1

primary_completion: 2026-12-31 → 2026-04-06

TRIUMPH-1

status: Active, not recruiting → Completed

TRIUMPH-3

intervention: — → Drug: Retatrutide; Drug: Placebo

TRIUMPH-3

status: Recruiting → Completed

TRIUMPH-3

enrollment: 1200 → 1946

TRIUMPH-3

primary_completion: 2027-09-30 → 2026-04-16

TRIUMPH-3

study_completion: — → 2026-05-14

TRIUMPH-3

primary_endpoints: — → Percent Change from Baseline in Body Weight

TRIUMPH-3

secondary_endpoints: — → Change from Baseline in Body Mass Index (BMI); Change from Baseline in Waist Circumference; Percent Change from Baseline in Total Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Systolic Blood Pressure (SBP); Change from Baseline in Diastolic Blood Pressure (DBP); Change from Baseline in Hemoglobin A1c (HbA1c); Percent Change from Baseline in Fasting Insulin; Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score; Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC)

TRIUMPH-3

comparator: — → Placebo

TRIUMPH-3

locations: — → 169 sites · Argentina, Australia, Canada, Hungary, Mexico, Poland, Puerto Rico, Slovakia, Spain, United States

TRIUMPH-2

locations: — → 98 sites · Argentina, Australia, Brazil, India, Mexico, Romania, Spain, United States

TRIUMPH-2

comparator: — → Placebo

TRIUMPH-2

intervention: — → Drug: Retatrutide; Drug: Placebo

TRIUMPH-2

secondary_endpoints: — → Change from Baseline in Body Mass Index (BMI); Change from Baseline in Waist Circumference; Change from Baseline in Systolic Blood Pressure (SBP); Change from Baseline in Diastolic Blood Pressure (DBP); Percent Change from Baseline in Total Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Hemoglobin (A1c) HbA1c %; Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score; Change from Baseline in Fasting Glucose; Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC); Percent Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset; A Hierarchical Combination of Functional Outcomes of Sleep Questionnaire (FOSQ) 10 score, FOSQ Vigilance Domain Score, and FOSQ Activity Level Domain Score for GSA2 Subset; Percentage of Participants with ≥50% AHI Reduction from Baseline for GSA2 Subset; Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA2 Subset

TRIUMPH-2

primary_endpoints: — → Percent Change from Baseline in Body Weight; Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset

TRIUMPH-2

study_completion: — → 2026-06-16

TRIUMPH-2

primary_completion: 2027-03-31 → 2026-06-16

TRIUMPH-2

enrollment: 1800 → 1152

TRIUMPH-2

status: Active, not recruiting → Completed

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

enrollment: 980 → 146

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

status: Recruiting → Completed

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

locations: — → 42 sites · Canada, Italy, Spain, United Kingdom, United States

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

comparator: — → Placebo

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

intervention: — → Drug: Retatrutide; Drug: Placebo

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

secondary_endpoints: — → Change from Baseline in Urine Albumin-to-Creatinine Ratio (UACR); Change from Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa); Change from Baseline in Filtration Fraction Estimated from Measured Glomerular Filtration Rate (mGFR); Change from Baseline in Renal Mean Arterial Flow as Assessed by Magnetic Resonance Imaging (MRI), Corrected by Hematocrit; Change from Baseline in in Mean Arterial Flow (MAF); Change from Baseline in Renal Artery Resistive Index (RARI); Change from Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) and End-diastolic Velocity (ESV); Change from Baseline in Global Renal Perfusion (MRI); Change from Baseline in Total Renal Parenchyma Volume (MRI); Change from Baseline in Renal Cortex Volume (MRI); Change from Baseline in Renal Cortex T1 (ms) (MRI); Change from Baseline in Medulla T1 (ms) (MRI); Change from Baseline in Renal Cortex R2 (BOLD MRI); Change from Baseline in Medulla R2; Change from Baseline in Body Weight; Change from Baseline in 24-hr Urinary Albumin Excretion (UAE); Change from Baseline in Change in 24-hour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h))

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

primary_endpoints: — → Change from Baseline in Glomerular Filtration Rate (mGFR)

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

study_completion: — → 2025-10-21

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

primary_completion: 2027-06-30 → 2025-10-01

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

phase: Phase 3 → Phase 2

TRIUMPH-5

enrollment: 760 → 800

TRIUMPH-5

primary_completion: 2027-12-31 → 2026-11-01

TRIUMPH-5

status: Recruiting → Active, not recruiting

TRIUMPH-5

study_completion: — → 2026-12-01

TRIUMPH-5

primary_endpoints: — → Percent Change from Baseline in Body Weight

TRIUMPH-5

secondary_endpoints: — → Change from Baseline in Body Mass Index (BMI); Change from Baseline in Waist Circumference; Percent Change from Baseline in Total Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Systolic Blood Pressure (SBP); Change from Baseline in Diastolic Blood Pressure (DBP); Change from Baseline in Hemoglobin A1c (HbA1c); Percent Change from Baseline in Fasting Insulin; Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)

TRIUMPH-5

intervention: — → Drug: Retatrutide; Drug: Tirzepatide

TRIUMPH-5

locations: — → 65 sites · Argentina, Germany, Poland, Puerto Rico, United States